Xiangxue Pharmaceutical Co Beneish M-Score Historical Data
The historical data trend for Xiangxue Pharmaceutical Co's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xiangxue Pharmaceutical Co Beneish M-Score Chart
|
Xiangxue Pharmaceutical Co Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Beneish M-Score |
|
Get a 7-Day Free Trial
|
|
|
-2.60 |
-2.13 |
-3.19 |
-3.38 |
-2.96 |
|
Xiangxue Pharmaceutical Co Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Beneish M-Score |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-3.33 |
-3.32 |
-2.69 |
-2.96 |
-2.88 |
Competitive Comparison of Xiangxue Pharmaceutical Co's Beneish M-Score
For the Biotechnology subindustry, Xiangxue Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xiangxue Pharmaceutical Co's Beneish M-Score Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xiangxue Pharmaceutical Co's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Xiangxue Pharmaceutical Co's Beneish M-Score falls into.
Xiangxue Pharmaceutical Co Beneish M-Score Calculation
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Xiangxue Pharmaceutical Co for today is based on a combination of the following eight different indices:
| M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
| = | -4.84 | + | 0.92 * 1.0387 | + | 0.528 * 0.887 | + | 0.404 * 0.902 | + | 0.892 * 1.0543 | + | 0.115 * 1 |
| - | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI |
| - | 0.172 * 0.9139 | + | 4.679 * -0.080512 | - | 0.327 * 1.062 |
| = | -2.88 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Mar24) TTM: | Last Year (Mar23) TTM: |
Total Receivables was ¥884 Mil.
Revenue was 568.857 + 571.106 + 526.829 + 612.628 = ¥2,279 Mil.
Gross Profit was 203.807 + 165.491 + 176.544 + 213.96 = ¥760 Mil.
Total Current Assets was ¥1,824 Mil.
Total Assets was ¥8,240 Mil.
Property, Plant and Equipment(Net PPE) was ¥4,578 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥399 Mil.
Total Current Liabilities was ¥5,153 Mil.
Long-Term Debt & Capital Lease Obligation was ¥580 Mil.
Net Income was -35.66 + -242.891 + -80.08 + -70.53 = ¥-429 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 25.814 + 71.473 + 39.42 + 97.571 = ¥234 Mil.
|
Total Receivables was ¥807 Mil.
Revenue was 588.725 + 441.469 + 554.612 + 577.269 = ¥2,162 Mil.
Gross Profit was 233.771 + 114.878 + 167.164 + 123.471 = ¥639 Mil.
Total Current Assets was ¥1,701 Mil.
Total Assets was ¥8,602 Mil.
Property, Plant and Equipment(Net PPE) was ¥4,775 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥414 Mil.
Total Current Liabilities was ¥5,186 Mil.
Long-Term Debt & Capital Lease Obligation was ¥449 Mil.
|
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
| DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
| = | (883.927 / 2279.42) | / | (807.155 / 2162.075) |
| = | 0.387786 | / | 0.373324 |
| | = | 1.0387 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
| GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
| = | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) |
| = | (639.284 / 2162.075) | / | (759.802 / 2279.42) |
| = | 0.295681 | / | 0.333331 |
| | = | 0.887 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
| AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
| = | (1 - (1823.787 + 4578.413) / 8240.218) | / | (1 - (1700.58 + 4774.574) / 8602.459) |
| = | 0.223055 | / | 0.24729 |
| | = | 0.902 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
| SGI | = | Sales_t | / | Sales_t-1 |
| = | Revenue_t | / | Revenue_t-1 |
| = | 2279.42 | / | 2162.075 |
| | = | 1.0543 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
| DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
| = | (0 / (0 + 4774.574)) | / | (0 / (0 + 4578.413)) |
| = | 0 | / | 0 |
| | = | 1 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
| SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
| = | (399.355 / 2279.42) | / | (414.482 / 2162.075) |
| = | 0.1752 | / | 0.191706 |
| | = | 0.9139 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
| LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
| = | ((579.562 + 5152.53) / 8240.218) | / | ((449.02 + 5185.912) / 8602.459) |
| = | 0.695624 | / | 0.655037 |
| | = | 1.062 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
| TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (-429.161 - 0 | - | 234.278) | / | 8240.218 |
| | = | -0.080512 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Xiangxue Pharmaceutical Co has a M-score of -2.88 suggests that the company is unlikely to be a manipulator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300147 has been successfully added to your